Top Emerging Wound Care Solution Companies - 2021
Sperry Bio: Donor-free Skin Replacement Done Right!

Top 10 Emerging Wound Care Solution Companies - 2021

Wound management is among healthcare’s considerable clinical concerns, with more people living with chronic wounds than the number of people affected by breast, colon, lung cancers, and leukemia combined. Despite their prevalence, accurate methods for assessing chronic wounds and tracking their progression have been slow to develop. This makes it difficult to judge the effectiveness of a given treatment, or make a timely decision to changing a course of treatment. But today, things are changing for the better. Several forward-looking companies are leveraging advanced machine learning technologies to create innovative tools that allow accurate wound area measurements with objective tissue composition analysis.

Alongside, from a diagnostic standpoint, AI is becoming a key driver to early detection and subsequent treatment of a host of health conditions, events ranging from cardiac arrest to wound care. AI-powered apps help patients with chronic wounds identify rashes, measure and analyze wounds. Moreover, with the increasing availabilities of massive data (wound images, wound-specific electronic health records) as well as powerful computing resources, AI-based digital platforms play a significant

role in delivering data-driven care to people suffering from debilitating chronic wounds.

Besides, collecting wound images on every clinical visit, interpreting it, and archiving the data can be cumbersome and time-consuming. Commercial platforms developed to capture images and high-resolution videos filmed on smartphones can now build 3D models of wounds and accurately calculate wound depth through machine learning. These insights provide a wealth of crucial clinical information, such as estimating skin substitutes needed for burn patients.

Highlighting these new developments in the wound care landscape, MedTech Outlook has compiled a list of emerging wound care solution companies that are at the top of their game. The enlisted organizations are transforming the healthcare landscape at the convergence of several disruptive technologies. Besides, the magazine also comprises insights from thought leaders in the sector on the industry trends, best practices, recent innovations, and their advice for aspiring CXOs.

We present to you MedTech Outlook’s “Top 10 Emerging Wound Care Solution Providers –2021”

    Top Emerging Wound Care Solution Companies

    Sperry Bio
    Vermont-based Sperry Bio has developed a skin replacement system that may solve these problems with its Sperry Micro-coring system. Unlike the traditional ways of skin grafting that replace the skin with the epidermis and a part of the dermis, Sperry Bio’s novel technology facilitates the implantation of full-thickness skin micro-columns, including reticular dermal fibroblasts, skin adnexa, adipose tissue, sweat glands, and hair follicles. These skin micro-column harvests result in less donor-site morbidity and help achieve durable single-stage skin replacement. The company’s Sperry Micro-coring system is a 510(k) surgical device that integrates 3D digital technology for transferring only a small percentage of the skin in the form of multiple round cores of full-thickness tissue
    Advamedica
    Advamedica is a deep science medtech company focused on biomaterial based medical devices. We combine our long biomaterials expertise with the power of proprietary manufacturing platform to develop novel hemostatic, surgical and wound care products. Current area of focus is in improving patient outcomes in pre-hospital, intra-operative, and post-operative clinical settings
    Arch Therapeutics
    (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. We intend to offer compelling options to healthcare institutions facing limited resources. Arch Therapeutics strives to be a leader in the field of stasis and barrier applications, including hemostasis and sealant products. We intend to develop products with dramatically improved profiles and characteristics over competing products. We intend to broaden the scope of the field by developing improved solutions to problems beyond the traditional hemostasis and sealant realms. Arch Therapeutics is focused on capital efficiency. Our operational plans are geared toward achieving value-creating milestones in a manner that optimizes quality, probability of success, and cost effectiveness. Arch Therapeutics believes in the value of intellectual property. We intend to file and defend patents and other intellectual property as required, in order to vigorously protect our assets, ideas, and inventions. Arch Therapeutics plans to achieve its mission with a small core team. The realization of our business objectives amidst the challenges of the modern healthcare environment requires that the best supporting people surround us. We value a healthy mix of seasoned entrepreneurs, scientists, business people and investors in a disciplined environment. Arch Therapeutics believes that by focusing on the above objectives, we will achieve the goal of providing an optimal return for our investors
    Arobella Medical
    Arobella Medical improves people’s lives by advancing the frontiers of medical technology. We improve lives by improving the quality of care that patients receive. By developing technology at the forefront of medical knowledge, we can apply that knowledge to current and emerging needs. We believe that advancing medical device technology requires both art and science. By encouraging creativity and innovation, we solve the problems of today and anticipate those of tomorrow
    Caladrius Biosciences
    Caladrius Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of cell therapies designed to reverse disease and/or promote the regeneration of damaged tissue. The Company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. The Company’s platform technology leverages these cells to enable the body’s natural repair mechanisms using formulations unique to each medical indication
    E-QURE
    E-QURE (Electric Quick Ulcer Remedy) developed a non-invasive, electrical stimulation (ES), medical device that cures Hard-to-Heal wounds and Ulcers. The Device mimics the actual Current of Injury surrounding the ulcer to enhance the wound self healing by the body. The Device is approved for marketing in many parts of the world. E-QURE is currently applying for FDA approval to market the device use in the USA. E-QURE is committed to advance the science of novel bioelectrical signals, discovered in humans, to innovative electrotherapies that create a new standard of care, restore health or even save lives
    Jigsaw Medical
    Jigsaw Medical strives to deliver safe, effective products and techniques for surgeons, physicians, and clinicians performing minimally invasive centesis procedures. We lead as a company by facilitating innovation and growth to efficiently bring new healthcare solutions to the table. Jigsaw Medical is based out of Sugar Grove, IL and specializes in manufacturing and distributing quality Vacuum Drainage Bottles, Evacuated Home Drainage Kits, Drain Lines, Drainage Accessories, and Surgical Knives to healthcare providers nationwide. Typically, our products are utilized in Radiology, Ultrasound, IR, Surgery, and other procedural departments. Our highly-equipped sales team is dedicated to personalized customer support and clinical expertise to solidify the integrity and dependability in our solutions. We value responsibility and collaboration with our customers to establish leadership and expansion in our field of expertise. Our commitment to putting each customer’s unique needs first gives us the ability to build long-term, meaningful partnerships and reduce treatment costs through simplifying patient care. For the better part of a decade, Jigsaw Medical has been demonstrating consistent advancements in specialized procedural medical equipment while also maintaining the highest standards of responsibility, collaboration, and care for our customers
    SuraMedical
    SuraMedical was born out of the 2016 Massachusetts Institute of Technology Grand Hack. Our main technical and sales and marketing resources are based in Minneapolis, Minnesota, which has a strong start-up environment as well as world-class medical device resources. Our main clinical resources are based in Boston, Massachusetts, which has a large wound care base of patients and clinics from which to draw. We aim to transform treatment of chronic wounds by shifting clinical practice and research paradigms. By arming providers and patients with insights to improve standard-of-care adherence, we will directly improve therapeutic outcomes. By enabling researchers to isolate the impact of variations in standard-of-care, we will accelerate the development of advanced solutions targeting the most difficult wounds
    ULURU
    ULURU is a specialty medical technology company committed to developing and commercializing innovative wound care and drug delivery systems based on our patented technologies. Our mission is to improve the lives of patients the world over by delivering comprehensive solutions that optimize outcomes for the key stakeholders in our healthcare systems: patients, providers and payers
    United Health Products
    United Health Products is a medical technology company focused on improving patient outcomes and reducing health care costs across the surgical, dialysis, dental, and emergency medicine sectors. We manufacture and distribute our patented hemostatic gauze, HemoStyp, which is derived from natural cellulose found in plant material. HemoStyp is an all-natural product designed to absorb exudate/drainage from wounds to help control bleeding. The hemostatic performance, benign impact on patient tissue and ease of use of our HemoStyp technology offers an unmatched value proposition to medical practitioners. HemoStyp has FDA 510(k) approval for human topical applications, dental procedures and veterinary surgeries. We are also well advanced in our application to the FDA for Premarket Approval (“PMA”) of HemoStyp as a Class III medical device which would allow HemoStyp to be used for internal bleeding during human surgical procedures. The FDA’s review is ongoing. In anticipation with this approval we are developing an expanded line of HemoStyp formats, including a flowable gel and powder, to cover the full range of surgical applications